STOCKHOLM, Sweden, Oct. 7, 2009 (GLOBE NEWSWIRE) -- Diamyd Medical announces today that 90 percent of the total 320 children and adolescents with type 1 diabetes due to participate in the company’s European Phase III study with the diabetes vaccine Diamyd(R) have now been included and have received injections of Diamyd(R) or placebo. The company expects all participants to have been included in the study by November 2009.
